Biodex stock slides 7% amid data for two drug studies

seekingalpha02-23

Shares of Biodexa (NASDAQ:BDRX) slid 7% in morning trading Friday after the biotech company reported study results for two of its therapy candidates. Biodexa said an in vitro preclinical study to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2413760373?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180743974/image_1180743974.jpg","is_english":true,"pubTime":"2024-02-23 23:07","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2413760373","market":"us","top_or_hot":-1,"title":"Biodex stock slides 7% amid data for two drug studies","media":"seekingalpha","content":"<div>\n<p>Shares of Biodexa (NASDAQ:BDRX) slid 7% in morning trading Friday after the biotech company reported study results for two of its therapy candidates. Biodexa said an in vitro preclinical study to ...</p>\n\n<a href=\"https://seekingalpha.com/news/4071104-biodex-stock-slides-amid-data-for-two-drug-studies\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biodex stock slides 7% amid data for two drug studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiodex stock slides 7% amid data for two drug studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-23 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4071104-biodex-stock-slides-amid-data-for-two-drug-studies><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Biodexa (NASDAQ:BDRX) slid 7% in morning trading Friday after the biotech company reported study results for two of its therapy candidates. Biodexa said an in vitro preclinical study to ...</p>\n\n<a href=\"https://seekingalpha.com/news/4071104-biodex-stock-slides-amid-data-for-two-drug-studies\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDRX","symbol_name":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD","start_time":0,"source_url":"https://seekingalpha.com/news/4071104-biodex-stock-slides-amid-data-for-two-drug-studies","article_id":"2413760373","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180743974/image_1180743974.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2413760373","pubTimestamp":1708700871,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Biodexa  slid 7% in morning trading Friday after the biotech company reported study results for two of its therapy candidates. Biodexa said an in vitro preclinical study to evaluate tolimidone’s potential for beta cell proliferation using reaggregated pancreatic islets was inconclusive. The company intends to move ahead with an in vivo study with similar objectives and a Phase 2a study of the therapy in patients with type 1 diabetes. The biotech company also reported topline results from a Phase 1 study of MTX110 in patients with diffuse midline glioma, or DMG. Of the nine patients who participated in the study, one experienced a severe adverse event that investigators assessed as not being related to the drug but instead to infusion and tumor anatomy, according to the company.  More on Biodexa Pharmaceuticals  Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Biodexa jumps on licensing deal for diabetes candidate Seeking Alpha’s Quant Rating on Biodexa Phar","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDRX":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD","BK4139":"生物科技"},"translate_title":"两项药物研究数据显示Biodex股价下跌7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDRX":1},"content_text":"Shares of Biodexa (NASDAQ:BDRX) slid 7% in morning trading Friday after the biotech company reported study results for two of its therapy candidates. Biodexa said an in vitro preclinical study to evaluate tolimidone’s potential for beta cell proliferation using reaggregated pancreatic islets was inconclusive. The company intends to move ahead with an in vivo study with similar objectives and a Phase 2a study of the therapy in patients with type 1 diabetes. The biotech company also reported topline results from a Phase 1 study of MTX110 in patients with diffuse midline glioma, or DMG. Of the nine patients who participated in the study, one experienced a severe adverse event that investigators assessed as not being related to the drug but instead to infusion and tumor anatomy, according to the company.  More on Biodexa Pharmaceuticals  Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Biodexa jumps on licensing deal for diabetes candidate Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2413760373"}